Literature DB >> 7804831

Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease.

I Tooyama1, E G McGeer, T Kawamata, H Kimura, P L McGeer.   

Abstract

A count of pigmented neurons per mm3 in sections of the substantia nigra at the level where the oculomotor nerve emerges in 11 neurologically normal controls aged 15-82 showed the expected slow loss of such neurons with age. Most (82 +/- 3.8%) of the pigmented neurons showed immunoreactivity for basic fibroblast growth factor (bFGF) and this percentage was unaffected by age. This is in marked contrast to the case in Parkinson's disease where only some 12.7 +/- 2.6% of the remaining dopaminergic neurons showed bFGF-like immunoreactivity, providing further evidence against the hypothesis that Parkinson's disease is due to some early insult followed by age-related attrition of the remaining neurons.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804831     DOI: 10.1016/0006-8993(94)91378-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.

Authors:  Dhruba J Bharali; Ilona Klejbor; Ewa K Stachowiak; Purnendu Dutta; Indrajit Roy; Navjot Kaur; Earl J Bergey; Paras N Prasad; Michal K Stachowiak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

2.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.

Authors:  Shih-Ling Hsuan; Heather M Klintworth; Zhengui Xia
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

4.  Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion.

Authors:  Marco Timmer; Konstantin Cesnulevicius; Christian Winkler; Julia Kolb; Esther Lipokatic-Takacs; Julia Jungnickel; Claudia Grothe
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

Review 5.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

6.  Morphometry of the human substantia nigra in ageing and Parkinson's disease.

Authors:  Gay Rudow; Richard O'Brien; Alena V Savonenko; Susan M Resnick; Alan B Zonderman; Olga Pletnikova; Laura Marsh; Ted M Dawson; Barbara J Crain; Mark J West; Juan C Troncoso
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

7.  Strain difference in the up-regulation of FGF-2 protein following a neurotoxic lesion of the nigrostriatal pathway.

Authors:  David M Yurek; Anita M Fletcher; Laura E Peters; Wayne A Cass
Journal:  Neurochem Res       Date:  2010-04       Impact factor: 3.996

8.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

Review 9.  Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations.

Authors:  Justine S Nicholson; Kyle S Landry
Journal:  Microorganisms       Date:  2022-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.